Harbin Medisan Pharmaceutical Co., Ltd.

Sümbol: 002900.SZ

SHZ

10.31

CNY

Turuhind täna

62.4601
P/E suhe
1.8348
PEG suhe
3.19B
MRK Cap
0.01%
DIV tootlus

Harbin Medisan Pharmaceutical Co., Ltd. (002900-SZ) Finantsaruanded

Q: Mis on ettevõtte kasumimarginaal?

Ettevõtte kasumimarginaal on .

Download

Aastane Quarterly

Lineaarne Log

Diagrammil näete Harbin Medisan Pharmaceutical Co., Ltd. (002900.SZ) vaikimisi numbreid dünaamikates. Companys revenue näitab keskmist NaN M, mis on NaN % gowth. Kogu perioodi keskmine brutokasum on NaN M, mis on NaN %. Keskmine brutokasumi suhtarv on NaN %. Ettevõtte eelmise aasta tulemuse puhaskasv on NaN %, mis on võrdne NaN % % keskmiselt kogu ettevõtte ajaloo jooksul.,

Aastane Quarterly

10Y 20Y 30Y 40Y

Bilanss

Sukeldudes Harbin Medisan Pharmaceutical Co., Ltd. fiskaalkäiguteele, täheldame keskmist varade kasvu. See määr on huvitaval kombel , mis kajastab nii ettevõtte kõrg- kui ka madalseisusid. Kui võrrelda kvartalite lõikes, siis kohandub see näitaja . Kui vaadata tagasi möödunud aastale, siis on varade kogumuutus NaN. Aktsionäride väärtus, mida näitab aktsionäride kogu omakapital, on hinnatud NaN aruandlusvaluutas. Selle aspekti aastane muutus on NaN%.

common:word.in-mln USD Growth	2022	2020	2018	2016	2014	2012
balance-sheet.row.cash-and-short-term-investments	1048.9	1293.9	1111.5	1022.2	1168.2	556.6	354.7	128.8	80.9	93.2	85.9	80.2
balance-sheet.row.short-term-investments	57.8	91.3	581.7	360.8	696.7	104.9	0	-4.1	0	0	-3.5	0
balance-sheet.row.net-receivables	150.6	164.1	149.6	204.7	256.1	249.8	192.2	109.6	97.4	108.9	140.8	135.2
balance-sheet.row.inventory	208.8	161.2	156.5	186.5	214.3	183.9	147.7	89.1	104.5	105.4	100.7	98.4
balance-sheet.row.other-current-assets	28.2	4.5	9.5	26.7	46.9	654.9	664.4	12.2	10	-2.4	-19.4	-16.1
balance-sheet.row.total-current-assets	1436.4	1623.7	1427.2	1440.2	1685.6	1645.2	1359	339.8	292.8	305.1	308.1	297.8
balance-sheet.row.property-plant-equipment-net	1081.6	882.4	925.3	867.3	806.7	725.7	721.7	722.6	671.6	571	456.5	332.3
balance-sheet.row.goodwill	1.3	0.5	9.4	9.4	9.4	9.4	9.4	9.4	9.4	10.8	10.8	10.3
balance-sheet.row.intangible-assets	141.2	71.7	62.5	66.4	70.1	72.6	50.6	51.8	52.7	53.7	54.6	62.6
balance-sheet.row.goodwill-and-intangible-assets	142.5	72.2	71.9	75.9	79.5	82	60.1	61.2	62.1	64.5	65.4	72.9
balance-sheet.row.long-term-investments	651.2	555.6	22.8	-345.9	-673.3	-72	0	8.1	0	0	7.6	3.2
balance-sheet.row.tax-assets	23.1	23.8	25.8	23.9	21.1	21.6	19.9	20.5	20.6	23.6	21	13.7
balance-sheet.row.other-non-current-assets	108.1	119.1	592.4	421.4	752.6	111.1	23	14	5.8	6.2	-0.8	-0.9
balance-sheet.row.total-non-current-assets	2006.5	1653.1	1638.3	1042.6	986.5	868.3	824.8	826.4	760.1	665.4	549.7	421.2
balance-sheet.row.other-assets	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-assets	3443	3276.8	3065.5	2482.8	2672.1	2513.6	2183.7	1166.2	1052.9	970.5	857.8	719
balance-sheet.row.account-payables	182.1	120.8	105.2	90	96.4	76.8	78	97	99.3	128.4	125.5	109.4
balance-sheet.row.short-term-debt	480.2	233.8	274.8	269.8	180	58	0	106	90	107	127	72
balance-sheet.row.tax-payables	3.1	12.2	11.2	10.8	31.9	19.1	46.1	27	13.8	8.8	42.6	33
balance-sheet.row.long-term-debt-total	238.2	422.9	212.9	10.9	0	0	0	0	0	0	0	0
Deferred Revenue Non Current	79	83.9	89	88.7	84.9	90.3	82.2	86.1	89.1	88.8	68.1	53.5
balance-sheet.row.deferred-tax-liabilities-non-current	-	-	-	-	-	-	-	-	-	-	-	-
balance-sheet.row.other-current-liab	7.9	188.3	2.5	2.1	96.7	293.3	188.6	20.7	18	13.6	27.3	35.6
balance-sheet.row.total-non-current-liabilities	449.7	627.1	412.4	102.3	97.1	96.6	82.2	86.1	89.1	88.8	68.1	53.5
balance-sheet.row.other-liabilities	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.capital-lease-obligations	8.3	5.1	8	10.9	0	0	0	0	0	0	0	0
balance-sheet.row.total-liab	1294.8	1224.8	949	691.2	820.4	543.8	348.8	358	325	361.3	492.6	376.3
balance-sheet.row.preferred-stock	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.common-stock	316.4	316.6	316.6	316.6	316.6	316.6	211.1	158.3	158.3	158.3	150	10.4
balance-sheet.row.retained-earnings	612.9	570.7	639.6	341.2	411.1	463	391.9	306.7	244.3	142.8	11.3	310.3
balance-sheet.row.accumulated-other-comprehensive-income-loss	0	162.5	192.3	164.5	152.1	0	0	0	0	0	0	0
balance-sheet.row.other-total-stockholders-equity	1211.2	990.9	952.9	952.9	952.9	1167.9	1232	343.2	325.3	308	203.8	15.2
balance-sheet.row.total-stockholders-equity	2140.5	2040.7	2101.4	1775.3	1832.7	1947.5	1834.9	808.2	728	609.2	365.1	335.9
balance-sheet.row.total-liabilities-and-stockholders-equity	3443	3276.8	3065.5	2482.8	2672.1	2513.6	2183.7	1166.2	1052.9	970.5	857.8	719
balance-sheet.row.minority-interest	7.7	11.3	15	16.3	19	22.3	0	0	0	0	0	6.9
balance-sheet.row.total-equity	2148.2	2052	2116.5	1791.6	1851.7	1969.8	-	-	-	-	-	-
balance-sheet.row.total-liabilities-and-total-equity	-	-	-	-	-	-	-	-	-	-	-	-
Total Investments	709	646.9	604.5	14.9	23.4	32.9	20	4.1	4.1	4.1	4.1	3.2
balance-sheet.row.total-debt	718.4	656.7	487.7	269.8	180	58	0	106	90	107	127	72
balance-sheet.row.net-debt	-272.8	-545.9	-42.2	-391.7	-291.5	-393.7	-354.7	-22.8	9.1	13.8	41.1	-8.2

Rahavoogude aruanne

Harbin Medisan Pharmaceutical Co., Ltd. finantsmaastikul on viimase perioodi jooksul toimunud märkimisväärne muutus vabas rahavoos, mis näitab NaN nihet. Ettevõte laiendas hiljuti oma aktsiakapitali, emiteerides NaN, mis tähistab NaN erinevust võrreldes eelmise aastaga. Ettevõtte investeerimistegevuse tulemusel kasutas ettevõte netosularaha, mis aruandlusvaluutas oli NaN. See on NaN nihkumine võrreldes eelmise aastaga. Samal perioodil registreeris ettevõte NaN, NaN, NaN, mis on olulised ettevõtte investeerimis-ja tagasimaksestrateegiate mõistmiseks. Ettevõtte finantseerimistegevuse tulemusel kasutas ettevõte netorahavahendeid NaN, kusjuures erinevus võrreldes eelmise aastaga oli NaN. Lisaks eraldas ettevõte NaN aktsionäridele dividendide maksmiseks. Samal ajal tegi ta muid finantsmanöövreid, millele viidatakse kui NaN, mis samuti mõjutasid oluliselt tema rahavooge sel perioodil. Need komponendid koos annavad tervikliku pildi ettevõtte finantsseisundist ja strateegilisest lähenemisest rahavoogude juhtimisele.

common:word.in-mln USD Growth	2021	2019	2017	2015	2013
cash-flows.row.net-income	26.5	349.7	26.6	173.9	204.4	181.1	175.2	166.3	147	104.4	82.7
cash-flows.row.depreciation-and-amortization	106.6	99.1	79.9	79	73.8	68.8	57.8	47.2	36.2	0	0
cash-flows.row.deferred-income-tax	11.7	95	-1.4	7.2	0	0	0	0	0	0	0
cash-flows.row.stock-based-compensation	-11.7	-95	1.4	-7.2	0	0	0	0	0	0	0
cash-flows.row.change-in-working-capital	49.5	107.4	-160.1	76.1	41.6	-9.2	-13.6	-10.2	-74.1	0	0
cash-flows.row.account-receivables	-10	49.6	49.1	-59	0	0	0	0	0	0	0
cash-flows.row.inventory	0.6	26.5	31.9	-33.6	-39	-60	13.7	0.9	-4.6	0	0
cash-flows.row.account-payables	47.2	-63.7	-239.6	161.6	0	0	0	0	0	0	0
cash-flows.row.other-working-capital	11.7	95	-1.4	7.2	80.7	50.8	-27.3	-11.1	-69.4	0	0
cash-flows.row.other-non-cash-items	-37.9	-568.8	49	-8.8	-27.4	-17.2	11.8	-2.4	7.2	-104.4	-82.7
cash-flows.row.net-cash-provided-by-operating-activities	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.investments-in-property-plant-an-equipment	-89.2	-73.9	-145.9	-198.6	-78.4	-104.9	-93.9	-141.7	-145.8	-154.1	-91
cash-flows.row.acquisitions-net	0.3	11.6	146.4	199.4	0	105	0	-0.5	8.4	-0.5	-5.7
cash-flows.row.purchases-of-investments	-72	-1113.7	-1091	-2271	-2482.1	-655	-14	0	0	-19.9	-40
cash-flows.row.sales-maturities-of-investments	580.2	901.9	1437.6	2340.9	2399.5	34.6	0	0	0	0.1	40.1
cash-flows.row.other-investing-activites	0	-4.1	-145.9	-198.6	0.6	-104.9	0.1	0	1.3	-0.1	0.1
cash-flows.row.net-cash-used-for-investing-activites	419.3	-278.2	201.3	-128	-160.5	-725.3	-107.8	-142.2	-136.1	-174.5	-96.5
cash-flows.row.debt-repayment	-270.2	-269.5	-230	-58	-30	-207	-90	-157	-207	-112	-96
cash-flows.row.common-stock-issued	0	0	0	85.8	0	0	0	0	0	0	0
cash-flows.row.common-stock-repurchased	0	0	0	-85.8	0	0	0	0	0	0	0
cash-flows.row.dividends-paid	-109.3	-34.3	-95.8	-209	-107.5	-92.4	-91.4	-54	-52.5	-42	-4.7
cash-flows.row.other-financing-activites	272.4	260.1	323.2	88.9	109.8	1020.7	115	141.9	290.1	161.3	115.6
cash-flows.row.net-cash-used-provided-by-financing-activities	-107.1	-43.7	-2.6	-178.1	-27.6	721.3	-66.4	-69.1	30.6	7.3	15
cash-flows.row.effect-of-forex-changes-on-cash	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.net-change-in-cash	456.8	-334.5	194.2	14.1	104.4	219.5	57	-10.4	10.8	-0.1	41.7
cash-flows.row.cash-at-end-of-period	782.3	325.5	660	465.7	451.7	347.3	127.8	70.9	81.3	70.5	70.5
cash-flows.row.cash-at-beginning-of-period	325.5	660	465.7	451.7	347.3	127.8	70.9	81.3	70.5	70.5	28.9
cash-flows.row.operating-cash-flow	144.6	-12.5	-4.5	320.1	292.5	223.5	231.2	200.8	116.3	0	0
cash-flows.row.capital-expenditure	-89.2	-73.9	-145.9	-198.6	-78.4	-104.9	-93.9	-141.7	-145.8	-154.1	-91
cash-flows.row.free-cash-flow	55.4	-86.5	-150.4	121.5	214	118.5	137.3	59.1	-29.5	-154.1	-91

Kasumiaruande rida

Harbin Medisan Pharmaceutical Co., Ltd. tulud muutusid võrreldes eelmise perioodiga NaN%. 002900.SZ brutokasum on teatatud NaN. Ettevõtte tegevuskulud on NaN, mille muutus võrreldes eelmise aastaga on NaN%. Kulud amortisatsioonikulud on NaN, mis on NaN% muutus võrreldes eelmise aruandeperioodiga. Tegevuskulud on teatatud NaN, mis näitab NaN% muutust võrreldes eelmise aastaga. Müügi- ja turunduskulud on NaN, mis on NaN% muutus võrreldes eelmise aastaga. Hiljutistel numbritel põhinev EBITDA on NaN, mis tähendab NaN% kasvu võrreldes eelmise aastaga. Tegevustulu on NaN, mis näitab NaN% muutust võrreldes eelmise aastaga. Puhaskasumi muutus on NaN%. Eelmise aasta puhaskasum oli NaN.

common:word.in-mln USD Growth	2022	2020	2018	2016	2014	2012
income-statement-row.row.total-revenue	1186.8	1028.4	945.8	1338.9	2102.1	2172.5	1148.8	760.9	722	681.5	601.2	491.2
income-statement-row.row.cost-of-revenue	476.4	365.6	309.4	491.3	509.9	352	296.7	290	275.9	287.4	280.7	268.5
income-statement-row.row.gross-profit	710.4	662.8	636.4	847.6	1592.1	1820.5	852.1	470.8	446.2	394.1	320.5	222.6
income-statement-row.row.gross-profit-ratio	0	0	0	0	0	0	0	0	0	0	0	0
income-statement-row.row.research-development	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-general-administrative	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-and-marketing-expenses	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-expenses	2.4	110.5	46.5	-11.1	27.2	-1.9	0.3	17.4	12	20	2.1	-6.6
income-statement-row.row.operating-expenses	693.4	679.6	765.2	786.5	1384.1	1604.9	619.5	264.5	263.4	226.3	174.1	108.5
income-statement-row.row.cost-and-expenses	1169.7	1045.1	1074.6	1277.8	1894	1956.9	916.2	554.5	539.3	513.8	454.9	377
income-statement-row.row.interest-income	27.9	28.3	11.8	10	8.5	14.9	1.7	0.7	0.6	0.7	0	0
income-statement-row.row.interest-expense	22.9	22.6	13.8	9.3	6.5	2	5	4.6	6.5	8	6.1	4.3
income-statement-row.row.selling-and-marketing-expenses	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.total-other-income-expensenet	2.4	-17.5	-1.9	-51.1	-0.6	33.5	20.4	2.8	15.3	6.7	-24.2	-19.5
income-statement-row.row.ebitda-ratio-caps	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-operating-expenses	2.4	110.5	46.5	-11.1	27.2	-1.9	0.3	17.4	12	20	2.1	-6.6
income-statement-row.row.total-operating-expenses	2.4	-17.5	-1.9	-51.1	-0.6	33.5	20.4	2.8	15.3	6.7	-24.2	-19.5
income-statement-row.row.interest-expense	22.9	22.6	13.8	9.3	6.5	2	5	4.6	6.5	8	6.1	4.3
income-statement-row.row.depreciation-and-amortization	108.7	106.6	122.9	79.9	75.8	73.8	68.8	57.8	47.2	36.2	45.2	19.6
income-statement-row.row.ebitda-caps	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.operating-income	79	57.6	454.8	84.2	228.8	251	252.7	197.8	186.9	163.6	121.4	103
income-statement-row.row.income-before-tax	81.4	40.1	452.9	33.2	228.2	249.1	253	209.1	198	174.5	122.2	94.6
income-statement-row.row.income-tax-expense	11.3	13.6	103.2	6.5	54.4	44.7	72	33.9	31.7	27.5	17.9	14.3
income-statement-row.row.net-income	73.7	30.2	351	29.3	177.2	205.8	181.1	175.2	166.3	147	104.4	82.7